Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CTSC | P53634 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29791111 | 0.98 | ALDH1A1 (0.48) | ALDH1A1HSD17B10CTSCCMA1F2 | |
| SCHEMBL31609177 | 0.96 | REN (0.53) | CMA1RENACESLC6A2 | |
| SCHEMBL6880524 | 0.91 | CTRB1 (0.48) | ALDH1A1HSD17B10CTSCCMA1F2 | |
| SCHEMBL6878588 | 0.91 | CTRB1 (0.48) | ALDH1A1HSD17B10CTSCCMA1F2 | |
| SCHEMBL14906464 | 0.91 | CTRB1 (0.48) | ALDH1A1HSD17B10CTSCCMA1F2 | |
| SCHEMBL14906471 | 0.91 | CTRB1 (0.48) | ALDH1A1HSD17B10CTSCCMA1F2 | |
| SCHEMBL6876472 | 0.91 | CTRB1 (0.48) | ALDH1A1HSD17B10CTSCCMA1F2 | |
| SCHEMBL6876603 | 0.91 | CTRB1 (0.48) | ALDH1A1HSD17B10CTSCCMA1F2 | |
| SCHEMBL31190175 | 0.91 | BDKRB2 (0.46) | ALDH1A1HSD17B10CTSCCMA1F2 | |
| SCHEMBL30630986 | 0.90 | REN (0.56) | CTSCCMA1RENACESLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022186290-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITOR | 森永乳業株式会社 | 2022-09-09 | — | — | WO | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20240317688-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-12012384-B2 | Dextrorphan prodrugs and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| WO-2022186290-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITOR | 森永乳業株式会社 | 2022-09-09 | — | — | WO | disclosed |
| WO-2022186290-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITOR | 森永乳業株式会社 | 2022-09-09 | — | — | WO | disclosed |
| US-20220089544-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012384-B2 | Dextrorphan prodrugs and processes for making and using them | OGFR, OPRM1, CYP4F3 | ALDH1A1 880/4885HSD17B10 451/4885CTSC 623/4885 |
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ALDH1A1 3596/4885HSD17B10 1839/4885CTSC 131/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ALDH1A1 4110/4885HSD17B10 3384/4885CTSC 37/4885 |
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | SLC16A3, SLC16A8, SLC16A1 | ALDH1A1 716/4885HSD17B10 133/4885CTSC 1597/4885 |
| US-20240317688-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRL1, OGFR | ALDH1A1 1015/4885HSD17B10 522/4885CTSC 378/4885 |
| US-20220089544-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OGFR, OPRM1, CYP4F3 | ALDH1A1 880/4885HSD17B10 451/4885CTSC 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.